Keywords: Amgen, Prolia, Osteoporosis, Fractures, Merck & Co, Odanacatib

New data on Amgen's Prolia and Merck & Co's odanacatib presented at ASBMR meeting

Article | 15 October 2012

Print This

Amgen (Nasdaq: AMGN), the world’s largest biotech firm, has presented data from several Prolia (denosumab) studies, including data ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in